Publication | Open Access

Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy

Endocrine-related CancerMedicineCancer ManagementGynecologyCancer TreatmentOncologyRadiation OncologyGynecology OncologyOlaparib MonotherapyGermline Brca1Ovarian CancerMutation Carriers